Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.43 |
| ▸ | FDPS | P14324 | 5/20 | 0.43 |
| ▸ | LAP3 | P28838 | 1/20 | 0.41 |
| ▸ | SGPL1 | O95470 | 4/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8620506 | 0.84 | S1PR1 (0.50) | TP53 | |
| SCHEMBL8620515 | 0.82 | POLB (0.46) | — | |
| SCHEMBL353227 | 0.80 | POLB (0.38) | TP53 | |
| SCHEMBL8621567 | 0.78 | FDPS (0.59) | TP53SMPD1FDPSLAP3LPAR3 | |
| SCHEMBL8659011 | 0.77 | FDFT1 (0.56) | — | |
| SCHEMBL4068245 | 0.77 | SMPD1 (0.47) | SMPD1FDPSLAP3SGPL1LPAR3 | |
| SCHEMBL8645070 | 0.75 | LPAR3 (0.36) | LPAR3LPAR1LPAR2 | |
| SCHEMBL8645068 | 0.75 | LPAR3 (0.36) | LPAR3LPAR1LPAR2 | |
| SCHEMBL8645074 | 0.75 | LPAR3 (0.36) | LPAR3LPAR1LPAR2 | |
| SCHEMBL15353194 | 0.74 | SMPD1 (0.44) | SMPD1FDPSLAP3LPAR3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |